Evidence map›Paper›PMID 29444493›Full record

ReviewCurrent opinion in virology2018

Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Aleksei Suslov, Stefan Wieland, Stephan Menne

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Recent Advances in Hepatitis B Treatment.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Aleksei SuslovDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel CH-4031, Switzerland.
Stefan WielandDepartment of Biomedicine, University Hospital Basel, University of Basel, Basel CH-4031, Switzerland. Electronic address: stefan.wieland@unibas.ch.
Stephan MenneDepartment of Microbiology & Immunology, Georgetown University Medical Center, Washington, DC 20057, United States. Electronic address: Stephan.Menne@georgetown.edu.
University of Basel · CHGeorgetown University Medical Center · US

Funding

NIAID NIH HHS HHSN272201000011I
6 · The paper itself

Abstract

The first line defense mechanisms against viral infection are mediated by the innate immune system. Viral components are detected by infected cells and/or innate immune cells that express different sensory receptors. They in turn mediate induction of direct antiviral mechanisms and further modulation of innate and adaptive immune responses. For evading the innate system, most viruses have evolved efficient mechanisms to block sensing and/or antiviral functions of the innate response. Interestingly, hepatitis B virus (HBV) seems to act like a stealth virus that escapes cell intrinsic antiviral mechanisms through avoiding recognition by the innate system rather than blocking its effector functions. In line with this concept, agonistic activation of innate immunity has emerged as a promising novel anti-HBV therapy approach with several compounds having advanced to the clinical stage.

Indexed as

AnimalsClinical Trials as TopicDisease Models, AnimalDrug Evaluation, PreclinicalHepatitis B, ChronicHepatitis B virusHumansImmunity, InnateImmunologic FactorsImmunologic Factors

Identifiers

PMID29444493
PMCPMC5988934
OpenAlexW2791098000

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.